Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best healthcare stocks with the highest upside. Viking Therapeutics, Inc. (NASDAQ:VKTX) received a Buy rating from Oppenheimer’s Jay Olson on October 7, who assigned a $100 price target to the stock’s shares. Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results H.C. Wainwright analyst Joseph Pantginis also reiterated a bullish stance on Viking Therapeutics, Inc. (NASDAQ:VKTX) on September 22, giving the stock a Buy rating wi ...

Core Insights - Viking Therapeutics, Inc. (NASDAQ:VKTX) is recognized as a high-potential biotech stock, with analysts maintaining a bullish outlook and setting price targets of $102 and $125 [1][3] - The company's strong market position is attributed to its competitive efficacy and safety data from its oral and subcutaneous GLP-1 programs, which are seen as significant strengths [2] Analyst Ratings - H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating for VKTX on September 22, with a price target of $102 [1] - BTIG analyst Justin Zelin also maintained a Buy rating, setting a higher price target of $125, emphasizing the company's solid position in the metabolic disease and obesity market [3] Company Overview - Viking Therapeutics, Inc. is a clinical-stage company focused on developing therapies for metabolic and endocrine disorders [3]

Core Viewpoint - Viking Therapeutics, Inc. (NASDAQ:VKTX) is identified as a strong buy stock by Wall Street, with a price target set at $125.00 by BTIG analyst Justin Zelin [1][2]. Company Position - Viking Therapeutics is well-positioned in the obesity and metabolic disease market, which is underscored by recent acquisitions in the sector, such as Pfizer's acquisition of Metsera, indicating the high valuation and strategic importance of companies in this field [2]. - The company is recognized as one of the few remaining independent players in the industry with an advanced and mature portfolio, making it an attractive target for potential acquisitions or partnerships [3]. Industry Context - Viking Therapeutics operates as a clinical-stage company focused on developing therapies for metabolic and endocrine disorders, highlighting its relevance in a growing market [4].